Dermatology · Astoria, NY
NPI
1891991147
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
30-16 30th Dr, Mezzanine
Astoria, NY, 11102
Phone (718) 728-3376
Groups this clinician bills Medicare through
Medicare paid, 2024
$119K
6,524 services
Medicare patients, 2024
280
Average age 75
Drug cost, 2024
$286K
1,301 prescriptions
Company payments, 2025
$2,427
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Lilly-Rose Paraskevas was code J7345 (aminolevulinic acid hcl for topical administration, 10% gel, 10 mg), 5,000 times for 16 patients. In total Lilly-Rose Paraskevas billed 6,524 services in 40 codes, and Medicare paid $119K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-11-07.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| J7345 Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg | Office | 5,000 | 16 | $1.33 | $6,663 |
| 17003 Destruction Skin Lesion | Office | 471 | 67 | $6.25 | $2,944 |
| 99214 Office E&M - Established | Office | 347 | 199 | $111.82 | $39K |
| 17000 Destruction Skin Lesion | Office | 169 | 85 | $57.97 | $9,797 |
| 11102 Skin Biopsy | Office | 95 | 77 | $89.40 | $8,493 |
| 99215 Office E&M - Established | Office | 87 | 72 | $154.27 | $13K |
| 17110 Destruction Skin Lesion | Office | 80 | 47 | $108.90 | $8,712 |
| 99204 Office E&M - New | Office | 62 | 62 | $130.04 | $8,062 |
| 99213 Office E&M - Established | Office | 56 | 46 | $76.41 | $4,279 |
| 96574 Skin | Office | 25 | 16 | $268.53 | $6,713 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 23 | 12 | $0.74 | $17.06 |
| 11900 Skin | Office | 23 | 12 | $49.81 | $1,146 |
| 99203 Office E&M - New | Office | 15 | 15 | $88.92 | $1,334 |
By year: 2022 $109K for 9,379 services; 2023 $123K for 10,675 services; 2024 $119K for 6,524 services.
Medicare prescription drug claims, 2024
In 2024, the drug Lilly-Rose Paraskevas prescribed most often to Medicare patients was Econazole Nitrate, with 262 prescriptions and refills. In total Lilly-Rose Paraskevas wrote 1,301 Medicare prescriptions that cost $286K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Econazole Nitrate Generic | 262 | 284 | 145 | $10K |
| Ketoconazole Generic | 242 | 248 | 91 | $3,660 |
| Triamcinolone Acetonide Generic | 168 | 177 | 88 | $1,486 |
| Fluocinonide Generic | 145 | 161 | 77 | $6,628 |
| Ammonium Lactate Generic | 139 | 151 | 79 | $2,295 |
| Clobetasol Propionate Generic | 42 | 44 | 22 | $2,743 |
| Hydrocortisone Generic | 31 | 31 | 22 | $150 |
| Valacyclovir Valacyclovir Hcl | 23 | 23 | 13 | $236 |
| Metronidazole Generic | 20 | 21 | 14 | $1,006 |
| Pimecrolimus Generic | 18 | 18 | Under 11 | $5,154 |
| Mupirocin Generic | 17 | 17 | 12 | $130 |
| Clindamycin Phosphate Generic | 17 | 17 | Under 11 | $1,114 |
| Tretinoin Generic | 17 | 17 | Under 11 | $752 |
| Ciclopirox Generic | 12 | 12 | Under 11 | $595 |
| Fluocinolone Acetonide Generic | 12 | 13 | Under 11 | $606 |
Brand drugs: 74 claims; generic drugs: 1,227 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Lilly-Rose Paraskevas $2,427 ($2,427 in general payments such as food, travel and fees) from 20 companies. The largest payer was Arcutis Biotherapeutics, Inc. with $338.
| Company | Payments | Amount |
|---|---|---|
| Arcutis Biotherapeutics, Inc. ARQT | 15 | $338 |
| Amgen Inc. AMGN | 15 | $285 |
| Janssen Biotech, Inc. JNJ | 12 | $271 |
| Botanix SB Inc | 14 | $257 |
| Incyte Corporation INCY | 11 | $246 |
| Revance Therapeutics, Inc. | 9 | $228 |
| LEO Pharma Inc. | 6 | $174 |
| Novartis Pharmaceuticals Corporation NVS | 5 | $104 |
| Genzyme Corporation SNY | 3 | $91.19 |
| Abbvie Inc. ABBV | 4 | $79.41 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.